FMI
MDGL icon

F/M Investments’s Madrigal Pharmaceuticals MDGL Stock Holding History

F/M Investments’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,738
Closed -$3.34M – 402
2025
Q4 		$3.34M Sell
5,738
-584
-9% -$298K 0.13% 182
2025
Q3 		$2.9M Buy
6,322
+265
+4% +$98.9K 0.11% 192
2025
Q2 		$1.83M Buy
6,057
+80
+1% +$23.8K 0.07% 253
2025
Q1 		$1.98M Buy
5,977
+3,718
+165% +$1.22M 0.08% 231
2024
Q4 		$697K Buy
+2,259
New +$635K 0.03% 309

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

F/M Investments's MDGL Position: Q1 2026 in Review

F/M Investments sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2026, closing a stake of 5,738 shares — an estimated $3.34M sold.

F/M Investments first reported a position in MDGL in Q4 2024 and held it in 5 quarters. The position peaked at $3.34M in Q4 2025. 380 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • F/M Investments reported no remaining Madrigal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • F/M Investments sold 5,738 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $3.34M.
  • F/M Investments first reported a position in Madrigal Pharmaceuticals in Q4 2024 and held it in 5 quarters.
  • F/M Investments's Madrigal Pharmaceuticals position peaked at $3.34M in Q4 2025.
  • 380 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on F/M Investments's 13F filing for Q1 2026, filed 11 May 2026.